About Evotec SE


Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and consulting arrangements. The Company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women’s health. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure.

Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB, and others. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with e.g. with Sanofi in the field of cancer immunotherapy, with Pfizer in the field of tissue fibrosis, with Bayer in the field of kidney diseases and women's health, as well as with Bristol Myers Squibb in the areas neurodegenerative diseases and oncology.

Evotec is built on integrated drug discovery know-how of over 20 years and is a leading player in the drug discovery field. The Company’s headquarters are located in Hamburg, Germany. Additional operating sites exist in Abingdon and Manchester, UK, Cologne, Goettingen and Munich, Germany, Verona, Italy, Branford, Princeton, Seattle and Watertown, USA, Lyon and Toulouse, France, as well as Orth/Donau, Austria. Evotec has more than 3,500 employees worldwide.


"Our high-quality drug discovery alliances combined with our vision and passion for innovation across various key disease areas accompany us on our path to lead this industry and to deliver on our growth strategy."Dr Werner Lanthaler, CEO of Evotec


Innovation Efficiency

The overall objective of Evotec is to become the global leader in high-quality drug discovery and development solutions. The execution of this strategy focuses on first-class innovation generated in partnerships with Pharma and biotech companies as well as with academia. In addition, the aim is to scale the business, develop optimal cost structures and achieve maximal operational efficiency.

From 01 January 2014 onwards, the Company has been operating and managing its business activities under the two segments EVT Execute and EVT Innovate:

EVT Execute

Evotec has evolved into one of the global leaders in providing complete drug discovery solutions on a stand-alone basis or through holistic, fully integrated drug discovery solutions. In EVT Execute, these services are provided on a typical fee-for-service basis only or through a variety of commercial structures including research fees, milestones and/or royalties, but with Evotec never taking development risks.


EVT Innovate

The segment EVT Innovate includes the advanced drug candidates and the early-stage internal discovery programmes. Evotec’s internal programmes focus on first-in-class and best-in-class projects based on innovative biology.

These so called “Cure X” or “Target X” initiatives largely follow indication areas that are firmly established at Evotec: metabolic and inflammatory disease, neurology, oncology, immuno-oncology and pain as well as infectious diseases. Projects are selected to match Evotec’s expertise and technology and positioned for partnering with Pharma customers, usually at pre-clinical stages. Ensuing partnerships usually involve upfront and research payments as well as milestones and product royalties. In the future, Evotec prepares to take unfunded development risks in this business segment, but only in very carefully selected projects and in early stage phases of drug discovery (pre-clinic).